

United States District Court
For the Northern District of California

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF CALIFORNIA

THE COUNTY OF SANTA CLARA, *et al.*,
on behalf of themselves and all others
similarly situated,

No. C 05-03740 WHA

Plaintiffs,

v.

ASTRA USA, INC., *et al.*,

Defendants.

**ORDER DENYING PLAINTIFF
SANTA CRUZ COUNTY'S MOTION
TO ALLOW DISCLOSURE OF
DISCOVERY PRODUCED IN THIS
ACTION TO THE GOVERNMENT
FOR USE IN FALSE CLAIMS ACT
ACTION**

INTRODUCTION

Now that the Supreme Court has held that plaintiffs lack standing to proceed with this action, plaintiff Santa Cruz County seeks to modify the protective order herein to allow it to use the discovery to fuel a lawsuit under the False Claims Act, 31 U.S.C. 3729 *et seq.* The motion is **DENIED.**

STATEMENT

The background of this action is set forth in many prior orders (*see, e.g.*, Dkt. Nos. 269, 364, 605). In brief, plaintiffs are operators of several 340B entities — health-care facilities to which drug manufacturers sell drugs at price ceilings pursuant to Section 340B of the Public Health Services Act, 42 U.S.C. 256b. Plaintiffs sued the defendant pharmaceutical companies alleging that they had overcharged 340B health-care facilities in violation of pharmaceutical pricing agreements between the companies and the Department of Health and Human Services. The suit was a proposed class action on behalf of both 340B entities in California and the

1 counties that fund those entities. Asserting that those entities were intended third-party
2 beneficiaries of the pharmaceutical pricing agreements, plaintiffs sought damages for breach of
3 contract.

4 An order by the undersigned judge dismissed the complaint because the pharmaceutical
5 pricing agreements confer no enforceable rights on 340B entities. The court of appeals reversed,
6 holding that covered entities, though they have no right to sue under the statute, could maintain
7 the action as third-party beneficiaries of the pharmaceutical pricing agreements. 588 F.3d 1237
8 (2009). The United States Supreme Court held unanimously that “suits by 340B entities to
9 enforce ceiling-price contracts running between drug manufacturers and the Secretary of [the
10 Department of Health and Human Services] are incompatible with the statutory regime,” thus
11 reversing the decision of the court of appeals. 131 S.Ct. 1342, 1345 (2011). The mandate has
12 not yet returned. Once it does, this case will be closed.

13 Preceding the original dismissal of this action by the undersigned judge in 2006, an order
14 approved a stipulated protective order (Dkt. No. 195). Substantial discovery was conducted and
15 documents produced subject to the protective order. Plaintiff Santa Cruz County now moves
16 “for an order modifying the Protective Order permitting the disclosure of evidence produced in
17 this action to the government for us[e] in connection[] with the filing of an action (or actions)
18 under seal.”

19 ANALYSIS

20 Plaintiff’s motion states: “As a result of having obtained and reviewed the discovery, . . .
21 plaintiff now has information in its possession that shows that some of the defendants, with
22 respect to some drugs, have submitted claims to the federal government that are in violation of
23 controlling contracts and regulations” (Br. 7). Though not explicitly so limited, it appears from
24 plaintiff’s motion that plaintiff intends — should its motion be granted — to file a False Claims
25 Act suit against defendants herein, alleging the same violations of law that the Supreme Court
26 has held plaintiff lacks standing to bring via its breach-of-contract claim.

27 Our court of appeals “strongly favors access to discovery materials to meet the needs of
28 parties engaged in collateral litigation. . . . Nonetheless, a court should not grant a collateral

1 litigant’s request for such modification automatically.” Modification of a protective order
2 requires consideration of the following: *First*, a court must consider whether “reasonable
3 restrictions on collateral disclosure will continue to protect an affected party’s legitimate
4 interests in privacy.” *Second*, plaintiff “must demonstrate the relevance of the protected
5 discovery to the collateral proceedings and its general discoverability therein.” *Third*, the court
6 “must weigh the countervailing reliance interest of the party opposing modification against the
7 policy of avoiding duplicative discovery.” *Foltz v. State Farm Mut. Auto. Ins. Co.*, 331 F.3d
8 1122, 1131–33 (9th Cir. 2003).

9 The *Foltz* decision concerned a motion by third-party intervenors who sought access to
10 documents to use them in collateral lawsuits involving similar claims to those made in the *Foltz*
11 litigation. There, unlike here, the documents were not improperly in the hands of the moving
12 party to begin with. No showing has been made as to the relevance of the protected discovery
13 and how it would demonstrate a false claim made to the government.

14 The United States is the real party in interest in all False Claims Act actions. The United
15 States is already well aware of this lawsuit and its contentions of over-billing. Indeed, this
16 lawsuit was originally provoked by press reports of government investigations into that subject.
17 There is little need for plaintiff to sue on behalf of the United States, for the United States is
18 already in a position to do so if it believes such an action is warranted. Note as well that,
19 although the United States participated as an amicus at several stages in this case, the United
20 States has not joined in the instant request.

21 Moreover, the Department of Health and Human Services has administrative procedures
22 that can be invoked by plaintiff to investigate over-charging. *See* 42 U.S.C. 256b(d)(3)(B)(iii)
23 (“a covered entity may discover and obtain such information and documents from manufacturers
24 and third parties as may be relevant to demonstrate the merits of a claim that charges for a
25 manufacturer’s product have exceeded the applicable ceiling price under this section, and may
26 submit such documents and information to the administrative official or body responsible for
27 adjudicating such claim”). Plaintiff has not requested that the discovery be allowed for use in
28 such a proceeding.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


On the other side of the ledger, the defendants were compelled herein to produce millions of pages of documents — over vehement objections. Inasmuch as defendants have now been vindicated by the United States Supreme Court in their original objections, the documents at issue are documents that plaintiff never should have had in the first place. It would further compound that wrong to let plaintiff use the same materials to fuel yet another lawsuit under the False Claims Act. The fair course is to restore the parties to the status quo ante this lawsuit and to let the United States bring its own False Claims Act action.

CONCLUSION

For the foregoing reasons, the motion is **DENIED**.

IT IS SO ORDERED.

Dated: July 20, 2011.



WILLIAM ALSUP
UNITED STATES DISTRICT JUDGE